Citizens raised the firm’s price target on Abivax (ABVX) to $131 from $114 and keeps an Outperform rating on the shares. Abivax reported Q3 ...

Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Investing.com -- Abivax SA (EPA:ABVX) shares dipped after the company reported a wider net loss for the first nine months amid higher research and administrative costs. The stock was down 5.7% by ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

Abivax (ABVX) stock rallies as market speculates about a potential takeover bid from Eli Lilly (LLY). Read more here.

PARIS, FRANCE / ACCESSWIRE / August 16, 2022 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system ...